NCT04620213View on ClinicalTrials.gov

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

December 23, 2020

Study Completion Date

March 15, 2021

Conditions
MydriasisDilation
Interventions
DRUG

Phentolamine Ophthalmic Solution 0.75%

0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

OTHER

Phentolamine Ophthalmic Solution Vehicle (Placebo)

Topical sterile ophthalmic solution

Trial Locations (12)

30075

Clinical Site 2, Roswell

32751

Clinical Site 6, Orlando

32779

Clinical Site 9, Longwood

38119

Clinical Site 4, Memphis

44195

Clinical Site 1, Cleveland

45242

Clinical Site 12, Cincinnati

45701

Clinical Site 5, Athens

66203

Clinical Site 3, Shawnee Mission

66762

Clinical Site 7, Pittsburg

92123

Clinical Site 10, San Diego

92663

Clinical Site 11, Newport Beach

02888

Clinical Site 8, Warwick

Sponsors
All Listed Sponsors
lead

Ocuphire Pharma, Inc.

INDUSTRY

NCT04620213 - Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis | Biotech Hunter | Biotech Hunter